ATAI

#2139
AtaiBeckley Inc. Common Stock
4.3300 USD
-0.23%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
4.3300
4.3300
年范围
3.2700
5.5000
日变化
-0.23%
每月变动
+28.49%
6个月变化
+9.62%
年变化
+9.62%
前一天收盘价
4.3400
开盘价
4.3300
最低价
4.3300
High
4.3300
交易量
64
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 1.5794 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry 生物技术
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-1.41
市销率
226.59

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

新闻